From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

After decades of research, gut microbiome therapies are beginning to reach the market. Here are 11 of the companies harnessing the power of the microbiome to develop treatments derived from the gut.

Named after French neurologist Georges Gilles de la Tourette, who first described the disorder in 1885, Tourette’s syndrome is estimated to affect one in 10 to 1000 people worldwide. A neurological ...

After being founded in 2017, 3T Biosciences debuted in 2022 with $40 million series A financing. As a company focused on immunotherapy, it is looking to change the future of treatment for solid tumors ...

As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden.

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...

AI has completely shifted the paradigm in the biotech industry. The past year has seen a gold rush in AI applications for the biopharma sector, for drug and protein discovery, or even treatment ...

The past year saw a string of pipeline cuts and downsizing plans strike the biotech job market. Have layoffs spooked young professionals looking for a way into the industry, and does the employment ...

Starting a biotech company is a daunting journey filled with both challenges and opportunities. Unlike many other industries, the path from idea to market in biotech can be particularly long. To build ...